DE2309329C2 - Verwendung von Äthyleniminlösungen als Inaktivierungsmittel bei der Herstellung von Impfstoffen - Google Patents

Verwendung von Äthyleniminlösungen als Inaktivierungsmittel bei der Herstellung von Impfstoffen

Info

Publication number
DE2309329C2
DE2309329C2 DE2309329A DE2309329A DE2309329C2 DE 2309329 C2 DE2309329 C2 DE 2309329C2 DE 2309329 A DE2309329 A DE 2309329A DE 2309329 A DE2309329 A DE 2309329A DE 2309329 C2 DE2309329 C2 DE 2309329C2
Authority
DE
Germany
Prior art keywords
ethyleneimine
vol
virus
solutions
vaccines
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
DE2309329A
Other languages
German (de)
English (en)
Other versions
DE2309329A1 (de
Inventor
Kurt Dr. Bauer
Horst Dr. 4041 Frixheim Geilhausen
Eckart Dr. 5600 Wuppertal Irion
Manfred Prof. Dr. 7400 Tuebingen Mussgay
Guenter Prof. Dr. Wittmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AG
Original Assignee
Bayer AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer AG filed Critical Bayer AG
Priority to DE2309329A priority Critical patent/DE2309329C2/de
Priority to BR1197/74A priority patent/BR7401197D0/pt
Priority to RO7400077745A priority patent/RO64304A/ro
Priority to CS741291A priority patent/CS191909B2/cs
Priority to HU74BA00003034A priority patent/HU171544B/hu
Priority to DK97974*#A priority patent/DK132766C/da
Priority to FR7406237A priority patent/FR2230346A1/fr
Priority to CA193,307A priority patent/CA1038757A/en
Priority to PL1974169031A priority patent/PL88703B1/pl
Priority to ES423617A priority patent/ES423617A1/es
Priority to IN401/CAL/74A priority patent/IN139338B/en
Publication of DE2309329A1 publication Critical patent/DE2309329A1/de
Priority to US05/617,038 priority patent/US4036952A/en
Priority to US05/617,037 priority patent/US4058599A/en
Application granted granted Critical
Publication of DE2309329C2 publication Critical patent/DE2309329C2/de
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32111—Aphthovirus, e.g. footandmouth disease virus
    • C12N2770/32161—Methods of inactivation or attenuation
    • C12N2770/32163—Methods of inactivation or attenuation by chemical treatment

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DE2309329A 1973-02-24 1973-02-24 Verwendung von Äthyleniminlösungen als Inaktivierungsmittel bei der Herstellung von Impfstoffen Expired DE2309329C2 (de)

Priority Applications (13)

Application Number Priority Date Filing Date Title
DE2309329A DE2309329C2 (de) 1973-02-24 1973-02-24 Verwendung von Äthyleniminlösungen als Inaktivierungsmittel bei der Herstellung von Impfstoffen
BR1197/74A BR7401197D0 (pt) 1973-02-24 1974-02-19 Processo para a fabricacao de preparacoes farmaceuticas
RO7400077745A RO64304A (fr) 1973-02-24 1974-02-19 Procede d'inactivite des suspensions des virus et des bacteries
CS741291A CS191909B2 (en) 1973-02-24 1974-02-21 Bayer ag.,de
DK97974*#A DK132766C (da) 1973-02-24 1974-02-22 Fremgangsmade til fremstilling af antigener eller immunogener til farmaceutiske preparater
FR7406237A FR2230346A1 (en) 1973-02-24 1974-02-22 Inactivating microorganisms with ethyleneimine - in the production of antigens or immunogens for pharmaceutical purposes
HU74BA00003034A HU171544B (hu) 1973-02-24 1974-02-22 Sposob poluchenija inaktivaciej vakcin virusov i bakterij
CA193,307A CA1038757A (en) 1973-02-24 1974-02-22 Ethyleneimine inactivated organisms
PL1974169031A PL88703B1 (cs) 1973-02-24 1974-02-23
ES423617A ES423617A1 (es) 1973-02-24 1974-02-25 Procedimiento para la obtencion de soluciones o suspensio- nes de virus y bacterias inactivadas.
IN401/CAL/74A IN139338B (cs) 1973-02-24 1974-02-26
US05/617,038 US4036952A (en) 1973-02-24 1975-09-26 Ethyleneimine inactivated microorganisms
US05/617,037 US4058599A (en) 1973-02-24 1975-09-26 Ethyleneimine inactivated organisms

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE2309329A DE2309329C2 (de) 1973-02-24 1973-02-24 Verwendung von Äthyleniminlösungen als Inaktivierungsmittel bei der Herstellung von Impfstoffen

Publications (2)

Publication Number Publication Date
DE2309329A1 DE2309329A1 (de) 1974-08-29
DE2309329C2 true DE2309329C2 (de) 1983-05-11

Family

ID=5873014

Family Applications (1)

Application Number Title Priority Date Filing Date
DE2309329A Expired DE2309329C2 (de) 1973-02-24 1973-02-24 Verwendung von Äthyleniminlösungen als Inaktivierungsmittel bei der Herstellung von Impfstoffen

Country Status (11)

Country Link
BR (1) BR7401197D0 (cs)
CA (1) CA1038757A (cs)
CS (1) CS191909B2 (cs)
DE (1) DE2309329C2 (cs)
DK (1) DK132766C (cs)
ES (1) ES423617A1 (cs)
FR (1) FR2230346A1 (cs)
HU (1) HU171544B (cs)
IN (1) IN139338B (cs)
PL (1) PL88703B1 (cs)
RO (1) RO64304A (cs)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LU78955A1 (de) * 1978-01-27 1979-09-06 Chimicasa Gmbh Verfahren zur inaktivierung von viren

Also Published As

Publication number Publication date
CA1038757A (en) 1978-09-19
DE2309329A1 (de) 1974-08-29
FR2230346B1 (cs) 1977-11-04
HU171544B (hu) 1978-02-28
DK132766B (da) 1976-02-02
PL88703B1 (cs) 1976-09-30
ES423617A1 (es) 1976-11-01
FR2230346A1 (en) 1974-12-20
DK132766C (da) 1976-07-05
RO64304A (fr) 1978-08-15
BR7401197D0 (pt) 1974-11-05
CS191909B2 (en) 1979-07-31
IN139338B (cs) 1976-06-05

Similar Documents

Publication Publication Date Title
AT408615B (de) Neue influenzavirus-impfstoffzusammensetzung
DE69227400T2 (de) Impfstoffe und Verfahren zu ihrer Herstellung
WO2000047222A2 (de) Inaktivierte influenza-virus-vakzine zur nasalen oder oralen applikation
DE69110082T2 (de) Untereinheit-Impfstoff gegen Actinobacillus Pleuropneumoniae.
EP0220387B1 (de) Konjugatimpfstoffe gegen Infektionen durch gramnegative Bakterien, Verfahren zu deren Herstellung sowie Verwendung derselben
DE69232969T2 (de) Methode zur herstellung von gram-negativen bakteriellen vakzinen
EP0173241B1 (de) Vakzine zur Behandlung der Harnwegsinfektionen
DE69216732T2 (de) Impfstoff gegen den Geflügelanämieerreger
DE2552137A1 (de) Attenuiertes felines calicivirus
DE2713371A1 (de) Impfstoff gegen die rhinotracheitis der katze und verfahren zu seiner herstellung
DE60226218T2 (de) Impfstoff gegen pferdeherpesvirus
DE3024282A1 (de) Vakzinierende glycopeptid-antigenfraktion mit grosser immunisierungsfaehigkeit, isoliert aus kulturen pathogener keime, verfahren zur isolierung dieser fraktion und diese enthaltende vakzinen
DE3853736T2 (de) Staupevirus-Impfstoff.
DE3541044A1 (de) Neues, allgemein anwendbares antigen (psc-a) gegen pseudomonas aeruginosa, das als mittel zum schutz gegen pseudomonas aeruginosa-infektion wirkt
DE69131525T2 (de) Pasteurella multocida toxoid enthaltende impfstoffe
DE2323847C3 (de) Lebendimpfstoff zur Immunisierung von Rindern gegen die Parainfluenza-3-Virus-Infektion
DE2553998C2 (de) Mumpsvaccin und Verfahren zu seiner Herstellung
DE2309329C2 (de) Verwendung von Äthyleniminlösungen als Inaktivierungsmittel bei der Herstellung von Impfstoffen
DE1617545C2 (de) Verwendung von informatorischer Ribonucleinsäure als Vaccine
DE3504940C2 (de) Multipotente Paramunitätsmediatoren, Verfahren zu ihrer Herstellung und diese Mediatoren enthaltende Arzneimittel
DE69116155T2 (de) Neuramidase und glulaktoseoxidase als vaccinadjuvans
DE4122906C2 (de) Impfstoffe gegen virale oder bakterielle Antigene und Verfahren zu ihrer Herstellung
DE2528584A1 (de) Verfahren zur inaktivierung der virusinfektiositaet unter gleichzeitiger stabilisierung von virusantigenen
DE2602478C3 (de) Impfstoff gegen die Panleukopenie der Feliden
DE3005495C2 (de) Herstellung von Fragmenten von Viren mit Lipidhülle und sie enthaltende Arzneimittelzubereitungen

Legal Events

Date Code Title Description
8126 Change of the secondary classification

Free format text: C12N 1/20 C12N 7/06

8181 Inventor (new situation)

Free format text: BAUER, KURT, DR. WITTMANN, GUENTER, PROF. DR. MUSSGAY, MANFRED, PROF. DR., 7400 TUEBINGEN, DE IRION, ECKART, DR., 5600 WUPPERTAL, DE GEILHAUSEN, HORST, DR., 4041 FRIXHEIM, DE

D2 Grant after examination
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee